TACE联合CIK治疗晚期肝癌患者疗效评价

doi:10.3969/j.issn.1672-5069.2017.02.016

摘要/Abstract

摘要： 目的探讨采用经肝动脉栓塞化疗术（TACE）联合应用细胞因子诱导的杀伤细胞（CIK）治疗晚期肝癌患者的临床疗效。方法我科2012年1月～2013年12月住院的原发性肝癌患者60例，被随机分为两组。30例患者在TACE治疗基础上给予CIK治疗，另30例患者仅接受TACE治疗。取患者自体外周血或健康产妇分娩脐血行CIK培养。在TACE治疗10～15 d后给予CIK细胞悬液（含1.0×109个细胞）外周静脉输注，连续或隔日输注1次，共3次。结果在治疗6 m时，联合组血清甲胎蛋白水平为（87.27±29.45） ng/ml，显著低于TACE组[（158.78±99.09） ng/ml，P＜0.05]|联合组肿瘤大小为（4.37±1.78）cm，也显著小于TACE组[（5.48±1.61）cm，P＜0.05]|治疗后3 m、6 m和9 m行影像学检查，联合组病灶无增多、增大，TACE组在治疗3 m后有4例出现肝内病灶增大|联合组2 a生存率为53.3%，显著高于TACE组的33.3%（P＜0.05）。结论 TACE联合CIK治疗晚期肝癌患者有一定的效果，患者耐受性良好，无严重不良反应，能明显提高患者生存率。

关键词: 原发性肝癌, 肝动脉栓塞化疗, 细胞因子诱导的杀伤细胞, 治疗

Abstract: Objective To investigate the clinical efficacy of cytokine-induced killer cells （CIK） combined with transcatheter arterial chemoembolization （TACE） for the treatment of patients with primary liver cancer （PLC）. Methods A total of 60 patients with PLC were enrolled in our hospital between January 2012 and December 2013. The patients were divided into two groups，and 30 patients were treated with TACE plus CIK，and another 30 were treated with TACE alone. The CIKs was obtained from autonomous peripheral blood or from healthy umbilical cord blood，and the cell suspensions were given 10 to 15 days after TACE with 1.0×109 cells each， once a day or once two days for three times. Results Serum fetoprotein level was（87.27±29.45） ng/ml in combination group six months after treatment，significantly lower than（158.78±99.09） ng/ml in TACE group（P＜0.05）；the tumor size was（4.37±1.78）cm in combination group，much smaller than [（5.48±1.61）cm，P＜0.05] in TACE group；the 2 a survival rate in combination group was 53.3%，much higher than 33.3% in TACE group （P＜0.05）. Conclusion CIKs treatment after TACE is an alternative approaches for patients with advanced liver cancer， which might prolong patients’ survival.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Cytokine-induced killer cells, Therapy

董静，陈照林，陈曦，刘波. TACE联合CIK治疗晚期肝癌患者疗效评价[J]. 实用肝脏病杂志, 2017, 20(2): 191-194.

Dong Jing，Chen Zhaolin，Chen Xi，et al.. Efficacy of TACE combined with CIK cells for the treatment of patients with advanced primary liver cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 191-194.

参考文献

[1] Ishida T，Murakami T，Shibata T，et al. Percutaneous microwave tumor coagulation for hepatocellular carcinomas with interruption of segmental hepatic blood flow. J Vasc Interv Radiol，2013，13（2 Pt 1）:185-191.
[2] Zhang J，Jin H，Liu H，et al. MiRNA-99a directly regulates AG02 through translational repression in hepatocelular carcinoma.Oncogenesis，2014，3:e97.
[3] 吴孟超，吴东. 原发性肝癌综合治疗得现状及展望. 癌症进展，2005，3（5）:410-412.
[4] 张福君，吴沛宏，赵明，等. 肝动脉栓塞化疗后射频消融联合酒精消融对原发性肝癌的疗效评价.中华肿瘤杂志，2013，27（4）:248-250.
[5] Fong Y，Sun RL，Jarnagin W，et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg，2013，229（6）:790-799.
[6] 中华人民共和国卫生部. 原发性肝癌诊疗规范（2011年版）. 临床肿瘤学杂志，2011，16（10）:929-946.
[7] Pacella CM，Bizzarri G，Magnolfi F，et al. Laser thermal ablation in the treatment of small hepatocellular carcinoma:results in 74 patients. Radiology，2013，221（3）:712-720.
[8] Burrel M，Reig M，Fomer A，et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation（TACE）using drug eluting beads:Implications for clinical practice and trial design. J Hepatol，2012，56（6）:1330-1335.
[9] Kawaguchi T，Ohkawa K，Imanaka K，et al. Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients. Hepatogastroenterology，2012，59（113）:219-223.
[10] Ladhams A，Schmidt C，Sing G，et al.Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol，2002，17（8）:889-896.
[11] 俞新爽，张建东，刘风军. 三维适形放疗联合TACE治疗晚期肝癌的临床疗效. 中国医药指南，2011，9（6）:177-178.
[12] Seki T，Wakabayashi M，Nakagawa T，et al. Percutaneous microwavecoagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer， 2013， 85（8）: 1694-702.
[13] 何文，梁晓宁，徐利群，等. 超声引导微波介入治疗大肝癌临床评价. 中华医学超声杂志，2013，1:13-15.
[14] Wallg D，ZhaIlg B，Gao H，et al． Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer．BMC Cancer，2014，14:251．
[15] Wang QJ，Wang H，Pan K，et a1．Comparative study on anti-tumor immune response of autologous cytokine-induced killer（CIK）cells，dendritic cells-CIK（DC-CIK），and semi-allogeneic DC-CIK．Chin J Cancer，2010，29（7）：641-648.
[16] 钱其军，吴孟超．肿瘤过继细胞治疗-老故事新演绎．中国肿瘤生物治疗杂志，2011，18（1）:1-5.
[17] Chen B，Xu XM，Xiang M，et al. Cytokine-induced killer cell combination with TACE in the treatment of hepatocellular cancers:a Meta-analysis. Chinese-German J Clin Oncol，2013，12（10）:459-467.
[18] 杨家进，吴建兵. 原发性肝癌综合介入治疗进展. 实用肝脏病杂志，2015，18（1）:118-119.
[19] Wright AS，Ampson LA，Arner TF，et al. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology，2013，36（1）:132-139.
[20] 马学斌，马聪，邱伟，等. CIK 细胞治疗90例肿瘤患者的安全性分析. 肿瘤学杂志，2014，20（3）:230-233.